Evolving Approaches for Protein Drug Delivery

Table of Contents

• Strategic Considerations
  • Stakeholder Implications
• Introduction
• Recent Milestones in Protein Drug Delivery
• Modifi cation of Protein Drugs to Improve Pharmacokinetics
  • Pegylation
  • Fusion Proteins
  • Amino Acid Substitution or Omission
• Discovery and Development of Novel Modifi ed Proteins
  • Novel Pegylated Protein Drugs
    • Nektar Therapeutics
    • Prolong Pharmaceuticals
  • Novel Fusion Protein Drugs
    • Human Genome Sciences
    • Syntonix Pharmaceuticals
  • Novel Bioengineered Protein Drugs
• Transdermal Systems and Subcutaneous Implants
  • Transdermal Delivery
    • Macrofl ux
    • Apogee Technology
    • Altea Therapeutics
    • Peptide Chaperone for Transdermal Delivery
    • MicroCHIPS
• Oral and Buccal Delivery
  • Unigene
  • Emisphere Technologies
  • Spherics Pharmaceuticals
  • Generex
  • DOR BioPharma
• Pulmonary and Intranasal Delivery
  • Pulmonary Insulin Products in Late-Stage Development
    • Alkermes/Eli Lilly
    • MannKind
    • Novo Nordisk
  • Emerging Pulmonary and Intranasal Drug Delivery Systems
    • Chrysalis Technologies
    • Aegis Therapeutics
• Outlook for Protein Drug Delivery

Tables:

• 1. Select Marketed Modifi ed Protein Drugs
• 2. Select Novel Modifi ed Protein Drugs in Development
• 3. Novel Transdermal Systems and Subcutaneous Implants
• 4. Novel Oral and Buccal Formulations of Protein and Peptide Drugs
• 5. Novel Pulmonary and Intranasal Formulations of Protein and Peptide Drugs

Figures:

• 1. Anatomy of the Skin
• 2. MicroCHIPS' s Implanted Drug Delivery Device
• 3. Schematic Representation of a Micelle and a Reverse Micelle